Free Trial

Veracyte (VCYT) Stock Forecast & Price Target

$23.93
-1.35 (-5.34%)
(As of 07/18/2024 ET)

Veracyte - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Based on 5 Wall Street analysts who have issued ratings for Veracyte in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 5 analysts, 1 has given a sell rating, and 4 have given a buy rating for VCYT.

Consensus Price Target

$27.50
14.92% Upside
High Forecast$34.00
Average Forecast$27.50
Low Forecast$21.00

According to the 5 analysts' twelve-month price targets for Veracyte, the average price target is $27.50. The highest price target for VCYT is $34.00, while the lowest price target for VCYT is $21.00. The average price target represents a forecasted upside of 14.92% from the current price of $23.93.

TypeCurrent Forecast
7/20/23 to 7/19/24
1 Month Ago
6/20/23 to 6/19/24
3 Months Ago
4/21/23 to 4/20/24
1 Year Ago
7/20/22 to 7/20/23
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
4 Buy rating(s)
4 Buy rating(s)
4 Buy rating(s)
4 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
1 Hold rating(s)
Sell
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
Consensus Price Target$27.50$27.50$29.00$30.20
Forecasted Upside14.92% Upside26.93% Upside28.93% Upside30.53% Upside
Get Veracyte Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for VCYT and its competitors with MarketBeat's FREE daily newsletter.

VCYT Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

VCYT Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Veracyte Stock vs. The Competition

TypeVeracyteMedical CompaniesS&P 500
Consensus Rating Score
2.60
2.72
2.51
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside14.92% Upside1,353.19% Upside9.09% Upside
News Sentiment RatingPositive News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
5/8/2024Needham & Company LLC
3 of 5 stars
 Lower TargetBuy ➝ Buy$33.00 ➝ $27.00+28.39%
4/15/2024The Goldman Sachs Group
2 of 5 stars
 Lower TargetBuy ➝ Buy$32.00 ➝ $28.00+41.34%
2/26/2024Morgan Stanley
3 of 5 stars
 Lower TargetUnderweight ➝ Underweight$22.00 ➝ $21.00-10.18%
2/23/2024William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform
10/10/2023Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOverweight ➝ Overweight$34.00+51.52%
1/18/2023Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOutperform ➝ Market Perform
1/4/2023Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageSector Outperform$33.00+38.83%
11/3/2022SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform$30.00 ➝ $35.00+79.49%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 01:14 AM ET.

VCYT Forecast - Frequently Asked Questions

What is Veracyte's forecast for 2024?

According to the research reports of 5 Wall Street equities research analysts, the average twelve-month stock price forecast for Veracyte is $27.50, with a high forecast of $34.00 and a low forecast of $21.00.

Should I buy or sell Veracyte stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Veracyte in the last year. There is currently 1 sell rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" VCYT shares.

Does Veracyte's stock price have much upside?

According to analysts, Veracyte's stock has a predicted upside of 26.93% based on their 12-month stock forecasts.

What analysts cover Veracyte?

Veracyte has been rated by research analysts at Needham & Company LLC in the past 90 days.

Do Wall Street analysts like Veracyte more than its competitors?

Analysts like Veracyte less than other "medical" companies. The consensus rating score for Veracyte is 2.60 while the average consensus rating score for "medical" companies is 2.72. Learn more on how VCYT compares to other companies.


This page (NASDAQ:VCYT) was last updated on 7/19/2024 by MarketBeat.com Staff

From Our Partners